Treatment with tocilizumab (Actemra) reduced the need for high-dose steroid treatment and increased the chance of remission for patients with giant cell arteritis, a randomised phase 3 trial shows. Results from the multicentre GiACTA trial were the basis for the Food and Drug Administration’s approval of tocilizumab to treat giant cell arteritis back in May. ...
Trial may herald “more ecstasy, less agony” for GCA patients
27 Jul 2017